Tien Liang Biotech Co., Ltd.(TW:4127)
NT$36.150.00 (0.00%)
TW:4127
Tien Liang Biotech Co., Ltd. financials statements
NT$36.15
At close:0.00 (0.00%)
Tien Liang Biotech Co., Ltd. (4127) Ratios
Tien Liang Biotech Co., Ltd. Ratios
TW:4127's free cash flow for Q2 2026 was NT$25.46M. For the 2026 fiscal year, TW:4127's free cash flow was decreased by NT$-1.52M and operating cash flow was NT$26.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.40 | 0.61 | 2.13 | 1.76 | 1.32 |
| Quick Ratio | 0.31 | 0.46 | 1.61 | 1.25 | 1.04 |
| Cash Ratio | 0.17 | 0.32 | 0.98 | 0.58 | 0.53 |
| Solvency Ratio | -0.00 | 0.05 | 0.18 | 0.35 | 0.24 |
| Operating Cash Flow Ratio | 0.05 | 0.12 | 0.48 | 0.12 | 0.20 |
| Short-Term Operating Cash Flow Coverage | 0.06 | 0.14 | 0.83 | 0.22 | 0.35 |
| Net Current Asset Value | NT$ -424.08M | NT$ -164.22M | NT$ 147.99M | NT$ 124.97M | NT$ 53.59M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.51 | 0.39 | 0.13 | 0.17 | 0.24 |
| Debt-to-Equity Ratio | 1.26 | 0.72 | 0.17 | 0.24 | 0.38 |
| Debt-to-Capital Ratio | 0.56 | 0.42 | 0.15 | 0.19 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.50 | 1.86 | 1.33 | 1.42 | 1.58 |
| Debt Service Coverage Ratio | -0.01 | 0.07 | 0.35 | 0.71 | 0.46 |
| Interest Coverage Ratio | -1.45 | 0.19 | 9.82 | 34.48 | 27.34 |
| Debt to Market Cap | 0.42 | 0.18 | 0.13 | 0.14 | 0.19 |
| Interest Debt Per Share | 13.32 | 7.61 | 1.90 | 2.53 | 3.47 |
| Net Debt to EBITDA | -78.48 | 8.42 | -1.85 | 0.09 | 0.61 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.29% | 59.69% | 62.21% | 63.68% | 59.21% |
| EBIT Margin | -3.15% | 4.20% | 4.46% | 11.03% | 7.52% |
| EBITDA Margin | -1.19% | 6.62% | 6.75% | 13.65% | 11.04% |
| Operating Profit Margin | -3.15% | 0.15% | 4.44% | 11.56% | 8.86% |
| Pretax Profit Margin | -2.30% | 3.40% | 4.00% | 11.23% | 8.54% |
| Net Profit Margin | -2.00% | 3.04% | 3.85% | 11.25% | 8.16% |
| Continuous Operations Profit Margin | -2.00% | 3.04% | 3.85% | 11.25% | 8.16% |
| Net Income Per EBT | 87.24% | 89.30% | 96.29% | 100.26% | 95.54% |
| EBT Per EBIT | 72.80% | 2208.60% | 90.12% | 97.10% | 96.34% |
| Return on Assets (ROA) | -0.87% | 1.32% | 2.71% | 8.79% | 7.11% |
| Return on Equity (ROE) | -2.16% | 2.45% | 3.60% | 12.52% | 11.26% |
| Return on Capital Employed (ROCE) | -3.40% | 0.12% | 4.01% | 12.45% | 11.74% |
| Return on Invested Capital (ROIC) | -1.31% | 0.06% | 3.32% | 10.33% | 8.60% |
| Return on Tangible Assets | -0.87% | 1.32% | 2.71% | 8.80% | 7.12% |
| Earnings Yield | -0.72% | 0.62% | 2.69% | 8.41% | 6.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.83 | 9.16 | 6.13 | 5.45 | 5.72 |
| Payables Turnover | 4.18 | 6.73 | 14.35 | 14.42 | 10.49 |
| Inventory Turnover | 3.49 | 2.66 | 2.29 | 2.02 | 3.82 |
| Fixed Asset Turnover | 1.51 | 1.19 | 1.38 | 1.56 | 1.63 |
| Asset Turnover | 0.43 | 0.43 | 0.70 | 0.78 | 0.87 |
| Working Capital Turnover Ratio | -1.75 | 230.04 | 3.02 | 5.00 | 14.03 |
| Cash Conversion Cycle | 50.97 | 123.09 | 193.24 | 222.28 | 124.53 |
| Days of Sales Outstanding | 33.69 | 39.84 | 59.54 | 67.03 | 63.85 |
| Days of Inventory Outstanding | 104.60 | 137.47 | 159.14 | 180.56 | 95.47 |
| Days of Payables Outstanding | 87.32 | 54.23 | 25.44 | 25.31 | 34.79 |
| Operating Cycle | 138.29 | 177.32 | 218.68 | 247.59 | 159.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.82 | 1.06 | 1.52 | 0.48 | 0.99 |
| Free Cash Flow Per Share | 0.31 | 0.97 | 1.41 | 0.46 | 0.97 |
| Dividend Paid and CapEx Coverage Ratio | 1.62 | 1.79 | 13.04 | 21.66 | 75.72 |
| Capital Expenditure Coverage Ratio | 1.62 | 11.68 | 13.04 | 21.66 | 75.72 |
| Operating Cash Flow Coverage Ratio | 0.06 | 0.14 | 0.82 | 0.19 | 0.29 |
| Operating Cash Flow to Sales Ratio | 0.07 | 0.13 | 0.15 | 0.04 | 0.08 |
| Free Cash Flow Yield | 1.01% | 2.33% | 9.76% | 2.95% | 6.59% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -140.91 | 159.62 | 36.92 | 11.88 | 14.51 |
| Price-to-Sales (P/S) Ratio | 2.77 | 4.93 | 1.43 | 1.34 | 1.19 |
| Price-to-Book (P/B) Ratio | 2.99 | 3.97 | 1.34 | 1.49 | 1.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 98.99 | 42.96 | 10.24 | 33.88 | 15.18 |
| Price-to-Operating Cash Flow Ratio | 37.80 | 39.28 | 9.46 | 32.31 | 14.98 |
| Price-to-Earnings Growth (PEG) Ratio | 0.76 | -4.79 | -0.53 | 0.43 | -0.08 |
| Enterprise Value Multiple | -312.26 | 82.91 | 19.37 | 9.89 | 11.35 |
| Enterprise Value | 1.89B | 2.11B | 601.39M | 713.28M | 715.65M |
| EV to EBITDA | -312.26 | 82.91 | 19.37 | 9.89 | 11.35 |
| EV to Sales | 3.70 | 5.49 | 1.31 | 1.35 | 1.25 |
| EV to Free Cash Flow | 132.22 | 47.82 | 9.35 | 34.18 | 16.04 |
| EV to Operating Cash Flow | 50.49 | 43.72 | 8.63 | 32.60 | 15.83 |
| Tangible Book Value Per Share | 10.35 | 10.43 | 10.76 | 10.38 | 9.03 |
| Shareholders’ Equity Per Share | 10.36 | 10.44 | 10.77 | 10.38 | 9.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.13 | 0.11 | 0.04 | -0.00 | 0.04 |
| Revenue Per Share | 11.18 | 8.42 | 10.05 | 11.55 | 12.49 |
| Net Income Per Share | -0.22 | 0.26 | 0.39 | 1.30 | 1.02 |
| Tax Burden | 0.87 | 0.89 | 0.96 | 1.00 | 0.96 |
| Interest Burden | 0.73 | 0.81 | 0.90 | 1.02 | 1.14 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.59 | 0.59 | 0.58 | 0.52 | 0.51 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -3.66 | 3.69 | 3.93 | 0.37 | 0.93 |
Currency in TWD
